Massimo Di Maïo
A5007575010- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Treatment and Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Ovarian cancer diagnosis and treatment
- Gastric Cancer Management and Outcomes
- Cancer survivorship and care
- Pancreatic and Hepatic Oncology Research
- Statistical Methods in Clinical Trials
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
- Advanced Breast Cancer Therapies
- PARP inhibition in cancer therapy
- Bladder and Urothelial Cancer Treatments
- Breast Cancer Treatment Studies
A. O. Ordine Mauriziano di Torino
2016-2025
University of Turin
2016-2025
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2023-2025
University of Siena
2017-2025
Fondazione Ricerca Molinette
2024-2025
Fondazione IRCCS Istituto Nazionale dei Tumori
2001-2024
Casa Sollievo della Sofferenza
2016-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2024
Centre Hospitalier Universitaire de Nîmes
2018-2024
Associazione Italiana Di Oncologia Medica
2003-2024
Information about symptomatic toxicities of anticancer treatments is not based on direct report by patients, but rather reports clinicians in trials. Given the potential for under-reporting, our aim was to compare reporting patients and physicians six (anorexia, nausea, vomiting, constipation, diarrhea, hair loss) within three randomized trials.In one trial, elderly with breast cancer received adjuvant chemotherapy; two trials, advanced non-small-cell lung first-line treatment. Toxicity...
Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo Italiano Pancreas 1 randomized phase III trial aimed to compare plus cisplatin versus alone (ClinicalTrials.gov ID NCT00813696).Patients locally or metastatic cancer, age 18 75 years, and Karnofsky performance status (KPS) > = 50, were randomly assigned receive (arm A) B). Arm A: 1,000 mg/m(2) weekly 7 weeks, and, a 1-week...
Erlotinib prolonged survival of unselected patients with advanced non-small-cell lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II studies suggested it might be an alternative to first-line chemotherapy. A randomized III trial was designed test whether erlotinib followed at progression by cisplatin-gemcitabine inferior in terms the standard inverse sequence.Patients stage IIIB (with pleural effusion or supraclavicular nodes) IV NSCLC performance status 0 1...
A proper estimation of the magnitude overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + is lacking because all trials that have investigated this regimen had primary end points other than OS. To test OS with higher power to explore interaction treatment effect main patient disease characteristics, we performed an individual data (IPD) meta-analysis.
Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given frequency of immune related adverse events and increasing use ICB, predictors response to CTLA-4 and/or PD-1 blockade represent unmet needs. Using a systems biology-based approach an assessment 779 paired blood tumor markers 37 stage III MMel patients, we analyzed association between parameters functional reactivity tumor-infiltrating cells after ex vivo...
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration irAEs in the literature is often incomplete.To investigate reporting incidence long-lasting irAEs, we reviewed all registration trials leading to ICI's approval by US FDA and/or EMA up December 2019. We analysed real-world data from lung (LC) melanoma (Mel) patients treated with approved ICIs at University Hospital Lausanne...
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative matter of debate. Methods We present the outcomes analysis according baseline (prior ICI initiation) putative immune-modulatory effects...
This is a multicenter, single-arm phase II trial evaluating the efficacy and safety of an immune-sensitizing strategy with temozolomide priming followed by combination low-dose ipilimumab nivolumab in patients microsatellite-stable (MSS) O6-methylguanine-DNA methyltransferase (MGMT)-silenced metastatic colorectal cancer (mCRC).Patients pretreated mCRC were centrally prescreened for MSS status MGMT silencing (ie, lack expression immunohistochemistry plus methylation pyrosequencing). Eligible...
Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than chemotherapy.Chemotherapy-naive stage IC to IV cancer (age ≤ 75 years; Eastern Cooperative Oncology Group performance status 2) were randomly assigned carboplatin area under curve (AUC) 5 plus paclitaxel...